Literature DB >> 20660214

Integration of Mycobacterium tuberculosis drug susceptibility testing and genotyping with epidemiological data analysis to gain insight into the epidemiology of drug-resistant tuberculosis in Malatya, Turkey.

Mansi Agarwal1, Selami Gunal, Riza Durmaz, Zhenhua Yang.   

Abstract

Drug-resistant tuberculosis (TB) presents a major challenge to global TB control. To gain a better understanding of drug-resistant TB epidemiology in Malatya, Turkey, we conducted the present study using 397 Mycobacterium tuberculosis clinical isolates collected from Malatya, Turkey, in recent years (2000-2007). Resistance to any anti-TB drug was found in 29% (114 of 397) of the study isolates, while the multidrug resistance (MDR) rate was approximately 4.5% (18 of 397). Resistances to isoniazid (15.5%) and streptomycin (13.4%) were about twice as high as resistance to rifampin (RMP) (6.3%) and ethambutol (EMB) (6.0%). Importantly, 28% (7 of 25) of the RMP-resistant isolates were non-MDR isolates, as when a significant proportion of RMP-resistant isolates in a population are non-MDR, the predictive value of molecular detection of RMP resistance for MDR can be significantly reduced. Both identical and varied drug resistance patterns were seen in the same genotyping-defined clusters, suggesting that both primary and acquired resistance have contributed to the drug-resistant TB epidemic in Malatya, Turkey. In addition, drug-resistant cases were found to be more likely to be males (odds ratio [95% confidence interval], 1.82 [1.13, 2.94]), suggesting a potential role of gender in the epidemiology of drug-resistant TB in the study population. This study demonstrates that the integration of drug susceptibility testing with genotyping and epidemiological data analysis represents a useful approach to studying the epidemiology of drug-resistant TB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660214      PMCID: PMC2937685          DOI: 10.1128/JCM.02459-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance.

Authors:  Y Samman; A Krayem; M Haidar; S Mimesh; A Osoba; A Al-Mowaallad; M Abdelaziz; S Wali
Journal:  Clin Microbiol Infect       Date:  2003-04       Impact factor: 8.067

Review 2.  Molecular epidemiology of tuberculosis.

Authors:  Peter F Barnes; M Donald Cave
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

Review 3.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

4.  High initial and acquired drug resistance in pulmonary tuberculosis in Turkey.

Authors:  K Tahaoğlu; O Kizkin; T Karagöz; M Tor; M Partal; T Sadoğlu
Journal:  Tuber Lung Dis       Date:  1994-10

5.  Mycobacterium tuberculosis drug resistance in Turkey, 1976-97.

Authors:  J S Bengisun; D Karnak; I Palabiyikoglu; N Saygun
Journal:  Scand J Infect Dis       Date:  2000

6.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.

Authors:  J Kamerbeek; L Schouls; A Kolk; M van Agterveld; D van Soolingen; S Kuijper; A Bunschoten; H Molhuizen; R Shaw; M Goyal; J van Embden
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

7.  Primary drug resistance and molecular epidemiology of Mycobacterium tuberculosis isolates from patients in a population with high tuberculosis incidence in Turkey.

Authors:  Riza Durmaz; Ibrahim Halil Ozerol; Bengul Durmaz; Selami Gunal; Aydin Senoglu; Ercument Evliyaoglu
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

Review 8.  Mechanisms of drug resistance in Mycobacterium tuberculosis.

Authors:  Y Zhang; W W Yew
Journal:  Int J Tuberc Lung Dis       Date:  2009-11       Impact factor: 2.373

9.  Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome.

Authors:  Suheyla Surucuoglu; Nuri Ozkutuk; Pinar Celik; Horu Gazi; Gonul Dinc; Semra Kurutepe; Galip Koroglu; Yavuz Havlucu; Gulgun Tuncay
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

10.  Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology.

Authors:  Karine Brudey; Jeffrey R Driscoll; Leen Rigouts; Wolfgang M Prodinger; Andrea Gori; Sahal A Al-Hajoj; Caroline Allix; Liselotte Aristimuño; Jyoti Arora; Viesturs Baumanis; Lothar Binder; Patricia Cafrune; Angel Cataldi; Soonfatt Cheong; Roland Diel; Christopher Ellermeier; Jason T Evans; Maryse Fauville-Dufaux; Séverine Ferdinand; Dario Garcia de Viedma; Carlo Garzelli; Lidia Gazzola; Harrison M Gomes; M Cristina Guttierez; Peter M Hawkey; Paul D van Helden; Gurujaj V Kadival; Barry N Kreiswirth; Kristin Kremer; Milan Kubin; Savita P Kulkarni; Benjamin Liens; Troels Lillebaek; Minh Ly Ho; Carlos Martin; Christian Martin; Igor Mokrousov; Olga Narvskaïa; Yun Fong Ngeow; Ludmilla Naumann; Stefan Niemann; Ida Parwati; Zeaur Rahim; Voahangy Rasolofo-Razanamparany; Tiana Rasolonavalona; M Lucia Rossetti; Sabine Rüsch-Gerdes; Anna Sajduda; Sofia Samper; Igor G Shemyakin; Urvashi B Singh; Akos Somoskovi; Robin A Skuce; Dick van Soolingen; Elisabeth M Streicher; Philip N Suffys; Enrico Tortoli; Tatjana Tracevska; Véronique Vincent; Tommie C Victor; Robin M Warren; Sook Fan Yap; Khadiza Zaman; Françoise Portaels; Nalin Rastogi; Christophe Sola
Journal:  BMC Microbiol       Date:  2006-03-06       Impact factor: 3.605

View more
  1 in total

Review 1.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.

Authors:  Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen
Journal:  Lancet       Date:  2014-03-24       Impact factor: 79.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.